J B CHEMICALS AND PHARMA

Kumud D Mody has submitted to the Exchange vide letter dated May 08, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Pranabh D Mody has submitted to the Exchange vide letter dated May 08, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shirish B Mody has submitted to the Exchange vide letter dated may 08, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Bharati S Mody has submitted to the Exchange vide letter dated May 08, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Nirav S Mody has submitted to the Exchange vide letter dated May 08, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

J. B. Mody, D. B. Mody, S. B. Mody has submitted to the Exchange vide letter dated April 06, 2015 a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Mr. Sanjay Asher, alternate director of the Company, has resigned from the board of directors of the Company with a view to ensure compliance with the ceiling on the number of directorship under the Companies Act, 2013.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per company's code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 1992, the trading window for dealing in the securities of the company will remain closed for all the directors/designated employees of the company from April 1, 2015 to May 24, 2015 (both days inclusive) in connection with declaration of the audited financial results for the quarter/year ending on March 31, 2015. This closure of trading window has already been notified to all the directors/ designated employees.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Hon'ble Bombay High Court has sanctioned the Scheme of Amalgamation and Arrangement between Jyotindra Mody Holdings Private Limited and Ansuya Mody Securities Private Limited and Dinesh Mody Securities Private Limited and Kumud Mody Securities Private Limited and Shirish B. Mody Investments Private Limited and Bharati S. Mody Investments Private Limited and J. B. Chemicals & Pharmaceuticals Limited and their respective shareholders under Sections 391 to 394 read with Sections 100 to 103 of the Companies Act, 1956 and Sec

JB Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 31-Dec-2014.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 4, 2015 titled "Unaudited Financial Results for Q3 - 2014-15".

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per company's code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 1992, the trading window for dealing in the securities of the company will remain closed for all the directors/designated employees of the company from January 1, 2015 to February 8, 2015 (both days inclusive) in connection with approval of the unaudited financial results for the quarter ending on December 31, 2014. This closure of trading window has already been notified to all the directors/ designated employees.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of Notice of hearing of petition for Scheme of Amalgamation and Arrangement published in news papers.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the board of directors of the company has appointed Mr. Devang R. Shah as an additional director of the company. He is an independent director on the board.

JB Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 30-Sep-2014.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 10, 2014, titled "Unaudited Financial Results Q2 -2014-15 ".

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Shri Bansidhar S. Mehta, a non-executive director of the company, has resigned from the board of directors of the company due to regulatory restrictions.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the outcome of meeting of equity shareholders convened under section 391 of the Companies Act, 1956-Clause 31(e) of the Listing Agreement.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the voting result of Postal Ballot and E-Voting-Clause 35A of the Listing Agreement.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of minutes of the Annual General Meeting of the Company held on September 15, 2014.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per company's code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 1992, the trading window for dealing in the securities of the company will remain closed for all the directors/designated employees of the company from October 1, 2014 to November 11, 2014 (both days inclusive) in connection with approval of the unaudited financial results for the quarter ended on September 30, 2014.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of notice of Postal Ballot and E-voting dated August 30, 2014 seeking approval of the equity shareholders of the Company to the said Scheme.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of notice (along with annexures thereto) dated August 30, 2014 for meeting of the equity shareholders of the Company convened u/s 391 of the Companies Act, 1956 pursuant to the Order made by the Hon ble High Court of Judicature at Bombay on August 22, 2014 ( said Order )

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange vide letter dated September 15, 2014 a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the details of voting results in the Annual General Meeting of the Company held on September 15, 2014, pursuant to clause 35A of the Listing Agreement.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange vide letter dated August 21, 2014 a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the Notice of the Annual General Meeting of the Company to be held on September 15, 2014.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Company has fixed Book Closure from September 6, 2014 to September 15, 2014 (both days inclusive) for the purpose of Annual General Meeting and Declaration of dividend.

JB Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 30-Jun-2014.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 5, 2014 titled "J.B. Chemicals reports robust bottom-line growth".

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange vide letter dated July 16, 2014 a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per companys code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 1992, the trading window for dealing in the securities of the company will remain closed for all the directors/designated employees of the company from July 1, 2014 to August 6, 2014 (both days inclusive) in connection with approval of the unaudited financial results for the quarter ending on June 30, 2014.This closure of trading window has already been notified to all the directors/ designated employees on June 27, 2014

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding date of payment of dividend.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the board of directors of the company at its meeting held on May 26, 2014 has recommended dividend @ Rs.3.00 (150%) per equity share of face value of Rs.2/-, for the financial year ended 2013-14. This together with dividend tax would absorb Rs. 2975.29 lacs. The dividend if declared, will be paid/ despatched on September 12, 2014.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of press release dated May 26, 2014 titled "Audited Financial Results for the year 2013-14."

JB Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2014.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the compensation committee of the board of directors of the company has, on May 21, 2014, issued and allotted 38,125 equity shares of face value of Rs. 2 each (6,750 shares at a premium of Rs. 82 per share and 31,375 shares at a premium of Rs. 93 per share) to certain employees against the exercise of options granted to them pursuant to Employees Stock Option Scheme of the company. The issued and paid up capital has thus gone up from 8,47,31,625 equity shares of Rs. 2 each to 8,47,69,750 equity shares of Rs. 2 each.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a Outcome of Board Meeting of the Company held on April 15, 2014.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per company s code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 1992, the trading window for dealing in the securities of the company has been closed for all the directors/designated employees of the company from April 1, 2014 to May 27, 2014 (both days inclusive) in relation to approval of audited financial results for the year ended on March 31, 2014.

JB Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 31-dec-2013.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that instead of re-opening the audited accounts for the year 2011-12 to reflect the adjustment of Rs. 64.50 crores, the company has now adjusted the said amount in the current financial year and the results for the quarter ended December 2013.

JB Chemicals & Pharmaceuticals Limited has submitted a copy of press release for the unaudited financial results for the quarter/ nine months ended on December 31, 2013.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange vide letter dated January 16, 2014 a copy of Disclosure under Regulation 13(2),13(2A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the board of directors of the Company has appointed Ms Krupa R. Gandhi, partner of Bansi S. Mehta & Co., Chartered Accountants, as an additional director of the Company. She is an independent director on the board.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Compensation Committee of the Board of Directors of the company has, on January 06, 2014, issued and allotted 19,825 equity shares of face value of Rs. 2 each (10,500 shares at a premium of Rs. 82 per share and 9,325 shares at a premium of Rs. 93 per share) to certain employees against the exercise of options granted to them pursuant to Employees Stock Option Scheme of the Company. The issued and paid up capital has thus gone up from 8,47,11,800 equity shares of Rs. 2 each to 8,47,31,625 equity shares of Rs. 2 each.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the compensation committee of the board of directors of the company has, on January 6, 2014, issued and allotted 19,825 equity shares of face value of Rs. 2 each (10,500 shares at a premium of Rs. 82 per share and 9,325 shares at a premium of Rs. 93 per share) to certain employees against the exercise of options granted to them pursuant to Employees Stock Option Scheme of the company.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange vide letter dated October 30, 2013 regarding a Re-opening of audited accounts.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 30, 2013, titled "Sales up by 17%, Profit from operations up by 61%; Unaudited Financial Results for Q 2- 2013-14".

JB Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 30-Sep-2013.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange, vide letter dated October 22, 2013 regarding a press release by the Company on ANDA approval received from US FDA for Tinidazole 250 mg and 500 mg tablets.